Contact

Pioneering Innovation

Our News

Amplity's new CEO Christina DiBiase
Read Now arrow
  • Press Release
  • Press Release

Amplity Names Christina DiBiase Chief Executive Officer

April 30, 2026

  • Company Updates
Filters

Filters

Type

News – Categories Filter Checkbox

Topic

News – Topics Filter Checkbox
  • Press Release
Read Article arrow

Amplity Showcases AI-Powered RWE Posters at ISPOR 2026

May 20, 2026
  • Research
Real-world research on how severity drives resource burden in OI.
Read Article arrow

How Severity Drives Resource Burden In OI

May 20, 2026
  • Research
Treatment of mNSCLC utilizes targeted therapy or chemotherapy and is often guided by molecular profiling.
Read Article arrow

Targeted Therapy Gap In EGFR+ mNSCLC

May 19, 2026
  • Research
Read Now arrow

Burden & Treatment Patterns Associated With Dravet And Lennox-Gastaut Syndromes

February 24, 2026
  • Research
Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, childhood-onset, developmental epileptic encephalopathies.
Explore Research arrow

Exploring The Clinical Burden Of Dravet Syndrome & Lennox-Gastaut Syndrome 

May 30, 2025
  • Research
Lung cancer is a common and deadly cancer in the United States.
Explore Research arrow

Streamlining NSCLC Patient Identification

May 21, 2025
  • Research
NLP Unlocks Patterns In Myasthenia Gravis Progression
Explore Research arrow

NLP Unlocks Patterns In Myasthenia Gravis Progression

May 21, 2025
  • Research
Myasthenia gravis (MG) is a rare, chronic, autoantibody-mediated neuromuscular disorder.
Explore Research arrow

Myasthenia Gravis Crisis: Treatment Challenges & Triggers 

May 21, 2025
  • Research
Usage of GLP-1 RAs can have side effects.
Explore Research arrow

GLP-1 RAs Usage: Trends In Adverse Events

May 15, 2025
  • Article
Read Article arrow

The 60-Second Data Story, Simple, Clear, Confident

May 26, 2026
  • Press Release
Read Article arrow

Amplity Showcases AI-Powered RWE Posters at ISPOR 2026

May 20, 2026
  • Research
Real-world research on how severity drives resource burden in OI.
Read Article arrow

How Severity Drives Resource Burden In OI

May 20, 2026
  • Research
Treatment of mNSCLC utilizes targeted therapy or chemotherapy and is often guided by molecular profiling.
Read Article arrow

Targeted Therapy Gap In EGFR+ mNSCLC

May 19, 2026

Who You’ll Be Working With

Our Senior Leaders Are With You Every Step Of The Way →

Events and Webinars

  • Conference

American Society Of Clinical Oncology (ASCO) Annual Meeting I Chicago, IL

  • May 29, 2026
  • - Jun 2, 2026
  • May 29, 2026
  • - Jun 2, 2026

•

  • Conference
  • Conference

Future Pharma I Boston, MA

  • Jun 1, 2026
  • - Jun 2, 2026
  • Jun 1, 2026
  • - Jun 2, 2026

•

  • Conference
  • Conference

Life Sciences Trainers & Educators Network (LTEN) Annual Conference I Orlando, FL

  • Jun 15, 2026
  • - Jun 18, 2026
  • Jun 15, 2026
  • - Jun 18, 2026

•

  • Conference
  • Webinar

How To Strengthen Launch Strategies With Medical-Commercial Collaboration

  • Jun 25, 2026
  • - Jun 25, 2026
  • Jun 25, 2026
  • - Jun 25, 2026

•

  • Webinar
Powerful Partnerships Start Here
Get in Touch